GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bridge Biotherapeutics Inc (XKRX:288330) » Definitions » Price-to-Owner-Earnings

Bridge Biotherapeutics (XKRX:288330) Price-to-Owner-Earnings : (As of May. 18, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bridge Biotherapeutics Price-to-Owner-Earnings?

As of today (2024-05-18), Bridge Biotherapeutics's share price is ₩2220.00. Bridge Biotherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Bridge Biotherapeutics's Price-to-Owner-Earnings or its related term are showing as below:


XKRX:288330's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-18), Bridge Biotherapeutics's share price is ₩2220.00. Bridge Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-1,726.00. Therefore, Bridge Biotherapeutics's PE Ratio for today is At Loss.

As of today (2024-05-18), Bridge Biotherapeutics's share price is ₩2220.00. Bridge Biotherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was ₩-1,726.00. Therefore, Bridge Biotherapeutics's PE Ratio without NRI for today is At Loss.

During the past 8 years, Bridge Biotherapeutics's highest PE Ratio without NRI was 28.44. The lowest was 0.00. And the median was 24.09.


Bridge Biotherapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Bridge Biotherapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bridge Biotherapeutics Price-to-Owner-Earnings Chart

Bridge Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Bridge Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bridge Biotherapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Bridge Biotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bridge Biotherapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bridge Biotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bridge Biotherapeutics's Price-to-Owner-Earnings falls into.



Bridge Biotherapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bridge Biotherapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2220.00/-1496.28
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bridge Biotherapeutics  (XKRX:288330) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Bridge Biotherapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Bridge Biotherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Bridge Biotherapeutics (XKRX:288330) Business Description

Traded in Other Exchanges
N/A
Address
58, Pangyo - ro, Gyeonggi No. 303, 255 beongil Seas Tower in Bundang Pangyo, Seongnam-si, KOR, 13486
Bridge Biotherapeutics Inc is a drug research and development company. It operates in the pharmaceutical and bio industry. The company has two pipeline clinical-stage products namely, BBT-401 and BBT-877.

Bridge Biotherapeutics (XKRX:288330) Headlines

No Headlines